NCT06160362 2023-12-07
The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)
Henan Cancer Hospital
Phase NA Unknown
Clinical Trials
9 trialsNCT04989335 2023-11-28
Bisantrene Combination for Resistant AML
Sheba Medical Center
Phase 2 Unknown
NCT05640713 2022-12-07
Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy
Henan Cancer Hospital
Phase 1 Unknown
NCT03648697 2020-08-11
EBV-TCR-T（YT-E001）for Patients With EBV-positive Recurrent or Metastatic NPC
Fujian Cancer Hospital
Phase 2 Unknown
NCT03412526 2019-04-04
Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian
Sheba Medical Center
Phase 2 Unknown
NCT02924753 2017-12-29
The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).
Henan Cancer Hospital
Phase 1 Unknown
NCT03322735 2017-12-29
Study of BCMA CAR-T in Multiple Myeloma
Henan Cancer Hospital
Phase 1/2 Unknown
NCT03263208 2017-10-20
CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
Henan Cancer Hospital
Phase 1/2 Unknown
NCT02275663 2015-01-06
Azacytidine Plus FLAG for Relapsed or Refractory AML
King Fahad Medical City
Phase 2 Unknown